Correction to: British Journal of Cancer (2009) 101, 598–604. doi:10.1038/sj.bjc.6605218 www.bjcancer.com
Upon publication of this paper in Volume 101, the authors noticed an error in the data contained within Table 3, taken from their original manuscript. The incidence of alopecia in CMF group should have been 39.3%, not 9.3%. The correct data are now shown, below.
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
Additional information
The online version of the original article can be found at 10.1038/sj.bjc.6605218
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Park, Y., Okamura, K., Mitsuyama, S. et al. Erratum: Uracil-tegafur and tamoxifen versus cyclophosphamide, methotrexate, fluorouracil, and tamoxifen in postoperative adjuvant therapy for stage I, II, or IIIA lymph node-positive breast cancer: a comparative study. Br J Cancer 101, 1031 (2009). https://doi.org/10.1038/sj.bjc.6605295
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6605295